sing Positron Emission Tomography (PET) imaging to measure kidney functio

Not Applicable

Completed

• Conditions: Kidney function; Renal and Urogenital - Kidney disease; Cancer - Any cancer

• Registration Number: ACTRN12613000845730
• Lead Sponsor: Dr Michael Hofman

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-08-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patient referred for Cr-51 EDTA study at our institution
- Age >= 18 years
- Written informed consent has been provided. One of the investigators will personally meet each candidate to explain the study and obtain written informed consent.

Exclusion Criteria

- Participant is not able to tolerate supine position on PET/CT bed for the duration of the PET/CT acquisitions, is not cooperative, or needs continuous nursing (e.g. patient from Intensive Care Unit).
- Pregnancy
- Breast-feeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Compare Ga-68 EDTA PET/CT calculated glomerular filtration rate (GFR) with results of Cr-51 EDTA. The GFR is calculated from the blood samples taken, and also from the PET scan.[Single time-point]

Secondary Outcome Measures

Name	Time	Method
Correlate assessment of differential or regional renal function with results of prior renal imaging. The contribution of each kidney to overall kidney function can be calculated from the PET scan. This will be compared to any prior tests that been performed for this purpose, usually a Tc-99m DMSA planar or SPECT/CT scan.[Single time-point]